1) American Psychiatric Association:Schizophrenia;2nd Edition;Practical Guidelines for the Treatment of Psychiatric Disorders, Compendium 2004. APA, Washington DC, pp249-439, 2004(松岡洋夫,佐藤光源,他 訳:統合失調症(第2版).佐藤光源,樋口輝彦,井上新平 監訳,米国精神医学会治療ガイドライン;コンペンディアム.医学書院,pp235-409, 2006)
2) Andreasen NC, Carpenter Jr WT, Kane KM, et al:Remission in schizophrenia:Proposed criteria and rationale for consensus. Am J Psychiatry 162:441-449, 2005
3) Bertelsen M, Jeppesen P, Petersen L, et al:Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness:The OPUS trial. Arch Gen Psychiatry 65:762-771, 2008
4) Bland RC, Parker JH, Orn H:Prognosis in schizophrenia:Prognostic predictors and outcome. Arch Gen Psychiatry 35:72-77, 1978
5) Brothers L:The social brain:A project for integrating primate behavior and neurophysiology in a new domain. Concepts in Neuroscience 1:27-51, 1990
6) Carpenter WT Jr:Targeting schizophrenia research to patient outcome. Am J Psychiatry 163:353-355, 2006
7) Carpenter WT, Koenig JI:The evolution of drug development in schizophrenia:Past issues and future opportunities. Neuropsychopharmacology 33:2061-2079, 2008
8) Cornblatt BA, Auther AM:Treating early psychosis:Who, what, when? Dialogues Clin Neurosci 7:39-49, 2005
9) Crumlish N, Whitty P, Clarke M, et al:Beyond the critical period:Longitudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatry 194:18-24, 2009
10) Davidson L, Schmutte T, Dinzero T, et al:Remission and recovery in schizophrenia:Practitioner and patient perspectives. Schizophr Bull 34:5-8, 2008
11) Dominguez MD, Saka MC, Lieb R, et al:Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis:A 10-year study. Am J Psychiatry 167:1075-1082, 2010
12) Fett A-K J, Viechtbauer W, Dominguez MG, et al:The relationship between neurocognition and social cognition with functional outcomes in schizophrenia:A meta-analysis. Neurosci Biobehav Rev 35:573-588, 2011
13) Green MF, Kern RS, Heaton RK:Longitudinal studies of cognition and functional outcome in schizophrenia:Implications for MATRICS. Schizophr Res 72:41-51, 2004
14) Häfner H, an der Heiden W, Behrens S, et al:Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr Bull 24:99-113, 1998
15) Häfner H, Maurer K, Trendler G, et al:Schizophrenia and depression:Challenging the paradigm of two separate diseases-A controlled study of schizophrenia, depression and healthy controls. Schizophr Res 77:11-24, 2005
16) Harvey PD, Bellack AS:Toward a terminology for functional recovery in schizophrenia:Is functional remission a viable concept? Schizophr Bull 35:300-306, 2009
17) Heinrichs RW, Ammari N, Miles A, et al:Psychopathology and cognition in divergent functional outcomes in schizophrenia. Schizophr Res 109:46-51, 2009
18) Heinrichs RW, Ammari N, Miles AA, et al:Cognitive performance and functional competence as predictors of community independence in schizophrenia. Schizophr Bull 36:381-387, 2010
19) Insel TR, Scolnick EM:Cure therapeutics and strategic prevention:Raising the bar for mental health research. Mol Psychiatry 11:11-17, 2006
20) Insel TR:Translating scientific opportunity into public health impact:A strategic plan for research on mental illness. Arch Gen Psychiatry 66:128-133, 2009
21) Insel TR:Rethinking schizophrenia. Nature 468:187-193, 2010
22) Jones PB, Barnes TRE, Davies L, et al:Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia:Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia study(CUtLASS 1). Arch Gen Psychiatry 63:1079-1087, 2006
23) Kasper S, Resinger E:Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 28(Suppl 1):27-38, 2003
24) Keefe RSE, Bilder RM, Davis SM, et al:Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633-647, 2007
25) Keefe RSE:Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 7:22-28, 2008
26) Klosterkötter J, Schultze-Lutter F, Ruhrmann S:Kraepelin and psychotic prodromal condition. Eur Arch Psychiatry Clin Neurosci 258(Suppl 2):74-84, 2008
27) Lieberman JA, Stroup TS, McEvoy JP, et al:Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223, 2005
28) Marshall M, Lewis S, Lockwood A, et al:Association between duration of untreated psychosis and outcome in cohorts of first-episode patients:A systematic review. Arch Gen Psychiatry 62:975-983, 2005
29) 松岡洋夫:統合失調症の認知障害:最近の話題.精神経誌 111:1148-1152, 2009
30) 松岡洋夫,松本和紀:精神疾患における認知機能.山内俊雄 編,精神疾患と認知機能.pp173-179,新興医学出版社,2009
31) 松岡洋夫,松本和紀:統合失調症の早期介入と予防:認知障害の視点.臨精薬理 13:3-11, 2010
32) 松岡洋夫,小松浩,本多奈美,他:統合失調症における認知機能障害に対する非定型抗精神病薬の有効性.薬局 61:69-74, 2010
33) Perkins DO, Gu H, Boteva K, et al:Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia:A critical review and meta-analysis. Am J Psychiatry 162:1785-1804, 2005
34) Pinkham AE, Penn DL, Perkins DO, et al:Implications for the neural basis of social cognition for the study of schizophrenia. Am J Psychiatry 160:815-824, 2003
35) Reichenberg A:Cognitive impairment as a risk factor for psychosis. Dialogues Clin Neurosci 7:31-38, 2005
36) Schimmelmann BG, Huber CG, Lambert M, et al:Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 42:982-990, 2008
37) Simon AE, Cattapan-Ludewig K, Zmilacher S, et al:Cognitive functioning in the schizophrenia prodrome. Schizophr Bull 33:761-771, 2007
38) Tandon R, Carpenter WT, Davis JM:First-and second-generation antipsychotics:Learning from CUtLASS and CATIE. Arch Gen Psychiatry 64:977-978, 2007
39) Tandon R, Belmaker RH, Gattaz WF, et al:World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100:20-38, 2008
40) van Os J, Burns T, Cavallaro R, et al:Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 113:91-95, 2006
41) van Os J, Kapur S:Schizophrenia. Lancet 374:635-645, 2009
42) Woodward ND, Purdon SE, Meltzer HY, et al:A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457-472, 2005
43) Wunderink L, Sytema S, Nienhuis FJ, et al:Clinical recovery in first-episode psychosis. Schizophr Bull 35:362-369, 2008